DYANAVEL XR 15
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DYANAVEL XR 15 (DYANAVEL XR 15).
Dyanavel XR contains amphetamine, which is a central nervous system stimulant that increases synaptic concentrations of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
| Metabolism | Amphetamine is metabolized primarily via hepatic cytochrome P450 enzymes, including CYP2D6, to metabolites such as 4-hydroxyamphetamine and norephedrine. Conjugation with glucuronic acid also occurs. |
| Excretion | Renal (80-90% as unchanged drug and metabolites, primarily dehydro-amphetamine); fecal excretion minimal (<5%) |
| Half-life | Terminal elimination half-life: amphetamine (d-isomer) 9-11 hours, l-isomer 11-14 hours; allows for once-daily dosing in extended-release formulation |
| Protein binding | 20-30% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 3.5-4.6 L/kg for amphetamine; indicates extensive tissue distribution |
| Bioavailability | Oral: ~100% for the immediate-release component; extended-release formulation provides equivalent AUC to same total dose of immediate-release given twice daily |
| Onset of Action | Oral (extended-release): 1-2 hours for measurable plasma concentrations; peak effect at 3-4 hours |
| Duration of Action | 12 hours (extended-release); provides coverage throughout the day with once-daily morning dose |
1-3 capsules orally once daily in the morning. Each capsule contains 15 mg of amphetamine (equivalent to 15 mg dextroamphetamine/amphetamine).
| Dosage form | TABLET, EXTENDED RELEASE |
| Renal impairment | No specific guideline; use with caution in severe renal impairment (GFR <30 mL/min) due to increased exposure; consider dose reduction. |
| Liver impairment | No specific Child-Pugh based modifications; use with caution in severe hepatic impairment due to potential for reduced clearance. |
| Pediatric use | For ages 13-17: start 1 capsule (15 mg) orally once daily in the morning; may increase by 15 mg weekly up to 30 mg/day. For ages 6-12: safety and efficacy not established, not recommended. |
| Geriatric use | Start at lower dose (e.g., 15 mg once daily) due to increased sensitivity; monitor for cardiovascular adverse effects and insomnia. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DYANAVEL XR 15 (DYANAVEL XR 15).
| Breastfeeding | Amphetamine is excreted into human breast milk. The estimated infant dose is approximately 5.6-13.9% of the maternal weight-adjusted dose, with an M/P ratio of 2.8-7.5. Peak milk concentrations occur 2-4 hours after a dose. Adverse effects in infants include irritability, poor sleeping, and poor weight gain. The American Academy of Pediatrics considers amphetamines as drugs of concern during breastfeeding. Avoid use if lactation is established; if essential, consider pumping and discarding milk for 4-6 hours after dosing. |
| Teratogenic Risk | First trimester: Mixed amphetamine salts have not been definitively linked to major congenital malformations; however, case-control studies suggest a small increased risk of oral clefts (adjusted OR 1.8; 95% CI 1.1-2.8) with first-trimester exposure. Second and third trimesters: Use may lead to fetal growth restriction (low birth weight, intrauterine growth restriction) and preterm delivery. Neonatal withdrawal syndrome (irritability, jitteriness, poor feeding) and premature labor or placental abruption may occur. Per ACOG, potential benefits may outweigh risks in carefully selected patients with severe ADHD. |
■ FDA Black Box Warning
WARNING: ABUSE, MISUSE, AND ADDICTION. CNS stimulants, including Dyanavel XR, have a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction. Misuse may cause serious cardiovascular adverse events and sudden death.
| Serious Effects |
["Known hypersensitivity to amphetamine or other components of the formulation.","Concurrent use or within 14 days of monoamine oxidase inhibitor (MAOI) use due to risk of hypertensive crisis.","Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, glaucoma.","Agitated states, history of drug abuse."]
| Precautions | ["Serious cardiovascular events including sudden death, stroke, and myocardial infarction have been reported with CNS stimulant use at recommended doses.","Blood pressure and heart rate may increase; monitor for hypertension and tachycardia.","Psychiatric adverse reactions, including exacerbation of psychosis, mania, and aggression, may occur.","Long-term suppression of growth (height and weight) has been observed; monitor growth during treatment.","Seizures may occur, especially in patients with a history of seizures.","Peripheral vasculopathy, including Raynaud's phenomenon, has been reported.","Serotonin syndrome risk when co-administered with serotonergic drugs."] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate, weight gain, and signs of preeclampsia. Serial fetal growth assessments via ultrasound every 3-4 weeks during the second and third trimesters to detect intrauterine growth restriction. Amniotic fluid volume assessment. Nonstress test or biophysical profile as clinically indicated. Obtain maternal ECG if tachycardia or hypertension is present. Monitor for preterm labor symptoms. |
| Fertility Effects | Amphetamines may impair fertility in females by causing ovulation dysfunction, possibly due to increased dopamine levels affecting prolactin and gonadotropin secretion. In males, long-term use may reduce sperm motility and count; these effects are likely reversible upon discontinuation. Limited human data; animal studies show reduced implantation rates at doses similar to human therapeutic levels. |
| Food/Dietary | High-fat meals delay the time to peak concentration (Tmax) by ~1 hour but do not affect overall exposure (AUC). Avoid acidic drinks (e.g., orange juice) consumption within 1 hour of dosing as they may reduce absorption. Do not take with antacids or acid-suppressing medications. |
| Clinical Pearls | DYANAVEL XR is a prodrug of amphetamine (lisdexamfetamine dimesylate) with a delayed onset due to rate-limiting hydrolysis. Onset is typically 1.5–2 hours post-dose. Avoid crushing or chewing beads; may be sprinkled on applesauce. Monitor for growth suppression in children; consider drug holidays. Contraindicated within 14 days of MAOIs. |
| Patient Advice | Take exactly as prescribed, once daily in the morning; avoid afternoon or evening doses to prevent insomnia. · Swallow capsule whole or sprinkle contents on applesauce; do not crush or chew. · Avoid alcohol while taking this medication. · Report worsening psychiatric symptoms, tics, or unusual changes in behavior. · Do not take food or antacids that alter gastric pH (e.g., high-fat meals, proton pump inhibitors) may affect absorption. · Store at room temperature; protect from moisture. |